Association of Bioscience Financial Officers Introduces Speaker Line-Up for 2019 National Conference Set for May 28-31 in Boston
BOSTON, MA / ACCESSWIRE / March 7, 2019 / The Association of Bioscience Financial Officers (ABFO), a national networking group for biotechnology, med tech and bioscience financial officers, today introduced the preliminary line-up of speakers for the 2019 National Conference. The event will be held May 28-31 at the Westin Copley Place in Boston.
To view the keynote speakers and the full multimedia interactive news release, click here.
About ABFO
Formed in 1989, the Association of Bioscience Financial Officers has multiple chapters that serve as forums for the exchange of information about the industry and networking. Regional chapters are based in top bioscience hubs to allow for face-to-face meetings and discussion of hot topics of interest to bioscience financial officers. The regional chapters meet annually at the ABFO National Conference for extended networking. For more information, visit http://www.abfointernational.org.
Media Contact:
Nicole Dragonetti, Russo Partners
nicole.dragonetti@russopartnersllc.com
(646) 942-5603
SOURCE: The Association of Bioscience Financial Officers
View source version on accesswire.com:
https://www.accesswire.com/538299/Association-of-Bioscience-Financial-Officers-Introduces-Speaker-Line-Up-for-2019-National-Conference-Set-for-May-28-31-in-Boston
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people…
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary…
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median…
Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV)…
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal…
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="337px" width="600px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="600px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
